—————————————————————-
Irritable bowel syndrome is the most common diagnosis in gastroenterology clinics and one of the most common reasons adults see a doctor for abdominal complaints. Prevalence estimates vary widely depending on how researchers define the condition: older, broader surveys suggested that roughly 10 to 15 percent of Americans — on the order of 25 to 45 million people — meet a loose definition of irritable bowel syndrome, while more recent studies using the stricter Rome IV criteria put the figure closer to 4 to 6 percent. A large 2025 study in Annals of Internal Medicine underscored both the substantial prevalence and the real quality-of-life burden of Rome IV IBS in the United States. Either way, IBS is a genuine disorder of gut-brain interaction, not a “wastebasket” label and not a moral failing of stress management. People with IBS show measurable differences in gut motility, visceral sensitivity, microbiome composition, and central pain processing compared with controls — even when every blood test looks pristine.
The condition is estimated to cost the US healthcare system tens of billions of dollars annually in direct and indirect costs, with figures around $30 billion often cited in summaries by the International Foundation for Gastrointestinal Disorders. This guide explains the four IBS subtypes, how doctors actually diagnose the condition, which dietary and pharmacologic approaches have evidence behind them, and when you should be evaluated for something more serious.
What IBS Is — and Isn’t
IBS is a chronic functional GI disorder defined by recurrent abdominal pain associated with changes in bowel habits. Doctors classify it into four subtypes based on the predominant stool form: IBS-C (constipation-predominant), IBS-D (diarrhea-predominant), IBS-M (mixed bowel habits), and IBS-U (unclassified). The older term “spastic colon” refers to the same condition. Roughly two-thirds of diagnosed patients are women, and most cases begin before age 50.
Critically, IBS does not damage the bowel, does not raise colon cancer risk, and does not progress to other diseases. That distinguishes it sharply from the inflammatory bowel diseases such as Crohn’s disease and ulcerative colitis, which involve visible inflammation, ulceration, and structural change. For a broader view of gut and chronic conditions, see our chronic conditions overview.
The Four Subtypes at a Glance
| Subtype | Predominant pattern | Typical first-line focus |
|---|---|---|
| IBS-C | Hard or lumpy stools, constipation | Soluble fiber, osmotic laxatives, secretagogues (prescriber-directed) |
| IBS-D | Loose or watery stools, diarrhea | Loperamide, dietary triggers, specific prescription options |
| IBS-M | Alternating constipation and diarrhea | Symptom-led approach, often diet plus neuromodulation |
| IBS-U | Symptoms that do not fit a clear pattern | Individualized; reassess over time |
This table is a general overview, not a treatment plan; subtypes can shift over time, and the right approach should be decided with a clinician.
The Rome IV Diagnostic Criteria
The Rome IV criteria, used worldwide and still current as of 2026, define IBS as recurrent abdominal pain on average at least one day per week over the past three months, associated with two or more of the following: a relationship to defecation, a change in stool frequency, or a change in stool form. Symptoms must have started at least six months before diagnosis. Doctors do not need a positive test to make the diagnosis; they apply the criteria and exclude alarm features. International guidance continues to evolve — for example the 2025 Seoul Consensus and the American College of Gastroenterology guideline — but the core diagnostic approach remains symptom-based with selective testing.
Alarm (“red flag”) features that argue against simple IBS and call for further workup include new onset after age 50, rectal bleeding or blood in the stool, iron-deficiency anemia, nocturnal diarrhea that wakes the patient from sleep, unintentional weight loss, a family history of colon cancer or inflammatory bowel disease, and progressive worsening. According to the NIDDK, tests such as fecal calprotectin and tissue transglutaminase IgA (to screen for celiac disease) are reasonable additions to basic labs in many workups. Your clinician decides which tests fit your situation.
What Causes IBS
The disorder is multifactorial, and no single cause explains every case. Roughly 10 to 15 percent of cases appear to follow an episode of acute gastroenteritis (post-infectious IBS). Visceral hypersensitivity — the gut sending pain signals at lower distension thresholds than normal — is well documented in IBS. Altered gut motility, dysregulation of the gut-brain axis, low-grade immune activation, and shifts in the gut microbiome all appear to contribute.
Anxiety and depression are more common in people with IBS and in some cases precede the GI symptoms by years. That does not mean IBS is “all in your head” — it means the gut and brain share neurotransmitters and stress pathways along the gut-brain axis. Adverse childhood experiences are associated with adult IBS, suggesting a developmental component in some people.
Diet: What Actually Works
The low-FODMAP diet has the strongest evidence of any dietary approach. FODMAPs (fermentable oligosaccharides, disaccharides, monosaccharides, and polyols) are short-chain carbohydrates that ferment in the intestine, draw water in, and produce gas. Studies summarized in peer-reviewed gastroenterology journals report that a majority of people with IBS — commonly cited as roughly half to three-quarters — improve during a strict elimination phase, though results vary and the diet is not a cure.
The diet is designed to work in three phases: about 4 to 6 weeks of strict elimination, then 6 to 8 weeks of structured reintroduction to identify personal triggers, and finally indefinite personalization. It is not meant to be followed in its strict form long term — that can risk nutritional gaps and unfavorable microbiome shifts. A registered dietitian familiar with FODMAPs is genuinely worth the visit, both to do the diet correctly and to avoid unnecessary restriction.
Other dietary moves with reasonable evidence include soluble fiber (such as psyllium) for IBS-C and IBS-M, enteric-coated peppermint oil capsules for cramping, limiting caffeine and alcohol, and avoiding very large or high-fat meals. Insoluble fiber and coarse bran tend to worsen symptoms in many people. Those who feel worse with gluten but do not have celiac disease may have non-celiac gluten sensitivity, although FODMAPs in wheat (fructans) often explain the symptoms — see our celiac disease guide for how clinicians sort out the differential before you cut out food groups.
Medications by Subtype
The options below are prescriber-directed. Doses and choices are individualized by a clinician who knows your history; the descriptions here are educational and are not a recommendation to start, stop, or adjust any medication on your own.
IBS with constipation
First-line, over-the-counter options include polyethylene glycol (Miralax) and soluble fiber. Prescription agents include linaclotide (Linzess), plecanatide (Trulance), lubiprostone (Amitiza), and tenapanor (Ibsrela); these increase intestinal fluid secretion or motility. In pivotal trials, response rates ran on the order of 30 to 40 percent, modestly above placebo, so expectations should be realistic and follow-up matters.
IBS with diarrhea
Loperamide can reduce stool frequency but generally does not help the pain component. Eluxadoline (Viberzi) and rifaximin (Xifaxan) are FDA-approved therapies for IBS-D. Rifaximin, a poorly absorbed antibiotic, produced durable improvement in roughly 40 percent of patients in trials after a 14-day course, with a repeat course available for relapse. Bile acid sequestrants (cholestyramine, colesevelam) may help the subset of IBS-D patients who actually have bile acid diarrhea, which a clinician can evaluate.
Pain and global symptoms
Low-dose tricyclic antidepressants (for example amitriptyline or nortriptyline) reduce IBS pain in multiple trials, working through gut-brain neuromodulation rather than mood elevation; a landmark UK primary-care trial (ATLANTIS) supported low-dose amitriptyline as a second-line option. Dosing is chosen and titrated by a prescriber, not self-directed. SSRIs can help patients with prominent anxiety. Antispasmodics such as dicyclomine and hyoscyamine offer short-term cramp relief for some people.
Brain-Gut Therapies
Cognitive behavioral therapy (CBT) tailored for IBS produces meaningful, sustained symptom reduction for many patients — often cited around 60 percent in trials. Gut-directed hypnotherapy has broadly comparable response rates. Both are now considered evidence-based and are recommended in the American College of Gastroenterology IBS guideline. Prescription digital therapeutics such as Mahana IBS have received FDA clearance and have made these approaches more accessible, though access and cost vary by insurer.
When to See a Doctor
If symptoms started after age 50, if you see blood, if you wake at night to use the bathroom, if you are becoming anemic, or if you are losing weight without trying, get evaluated — these are not typical IBS features and can point to other conditions. New onset after 50 in particular usually prompts a clinician to rule out colorectal and other causes. If you have been diagnosed with IBS but standard treatments have not helped after several months, it is reasonable to revisit the diagnosis: small intestinal bacterial overgrowth, microscopic colitis, bile acid diarrhea, celiac disease, and food allergies can all mimic IBS and have specific treatments.
Frequently Asked Questions
Is IBS the same as IBD?
No. IBS is a functional disorder with no visible inflammation or structural damage. IBD — Crohn’s disease and ulcerative colitis — involves measurable inflammation, ulceration, and increased cancer risk. Fecal calprotectin testing helps distinguish the two when there is uncertainty.
Can stress cause IBS?
Stress is not thought to cause IBS by itself, but it commonly amplifies symptoms through the gut-brain axis. Many people find their flares track work stress, poor sleep, and travel. CBT and gut-directed hypnotherapy directly target these pathways.
How long does IBS last?
IBS is chronic and tends to wax and wane over years. Broadly, some patients enter sustained remission, some have intermittent symptoms, and some have persistent symptoms. Importantly, the condition does not damage the bowel regardless of how long it lasts.
Is there a cure for IBS?
There is no known cure, and you should be skeptical of any product that promises one. The realistic goal is good symptom control through a combination of diet, targeted medication, and brain-gut therapy, tailored to your subtype and worked out with a clinician over time.
What is the difference between IBS-D and IBD?
IBS-D causes diarrhea without bleeding, inflammation, weight loss, or nocturnal symptoms. IBD frequently causes bloody stools, weight loss, and night-time diarrhea, with elevated inflammatory markers. Colonoscopy and calprotectin testing reliably separate them.
Quick summary: IBS is a common, chronic disorder of gut-brain interaction with four subtypes. It is diagnosed clinically using the Rome IV criteria after alarm features are excluded, and it does not damage the bowel or cause cancer. The low-FODMAP diet, subtype-specific medications, and brain-gut therapies help most people manage symptoms, but there is no cure and medications should be prescriber-directed. This article is educational and is not a substitute for care from a qualified clinician. Seek prompt evaluation for rectal bleeding, unintentional weight loss, anemia, nocturnal diarrhea, or new symptoms after age 50.
What to Do Next
If you suspect IBS, do not settle for “stress” as the whole explanation. Work with a clinician to confirm the diagnosis with the Rome IV criteria, rule out alarm features, and consider a supervised low-FODMAP elimination phase with a dietitian. If diet alone is not enough, the prescription menu has expanded substantially over the last decade, and effective brain-gut neuromodulators exist for chronic, refractory symptoms. If you have been on the same antispasmodic for years without improvement, that is a good prompt to revisit your plan with your doctor rather than a reason to give up.